Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Camillo Porta, Lorenza Rimassa et al.|The Lancet Oncology|2012Cited by 550
Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsDirk Strumberg, Brian Schwartz, Heinz‐Josef Lenz et al.|The Oncologist|2007Cited by 418
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung CancerLecia V. Sequist, Joan H. Schiller, Joachim von Pawel et al.|Journal of Clinical Oncology|2011Cited by 379
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Yi Yu, Brian Schwartz|PLoS ONE|2015Cited by 121